1.1Eight-hour biomass production
A concentrated inoculum seeds a stirred vessel containing glucose and yeast extract. The vessel runs at 35 °C with pH control at 6.0 to limit acid inhibition during biomass growth.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A concentrated inoculum seeds a stirred vessel containing glucose and yeast extract. The vessel runs at 35 °C with pH control at 6.0 to limit acid inhibition during biomass growth.
A pump transfers the cells and spent medium together into a second vessel. A measured addition of water and buffer dilutes carryover nutrients and sets the starting pH for the second stage.
The recovered cells enter a phosphate-buffered solution containing glucose and a defined amino acid mixture. The glucose supplies fermentable carbon, and pH control limits acidification as lactate accumulates.
Liquid chromatography measures selected soluble metabolites in a reference sample. The formulation liquid is prepared by dissolving purified forms of those metabolites in water at the measured concentrations.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A cosmetic materials laboratory prepares the two-stage fermentation filtrate and blends it into saline. The saline preparation serves as the liquid phase of a hydroxyethyl cellulose hydrogel. A rotational viscometer measures viscosity after mixing and during storage, and visual inspection records any phase separation.
A tangential flow microfiltration module replaces the first centrifuge. The first culture circulates through a hollow-fiber membrane that retains bacterial cells while the first supernatant passes into a collection vessel. The retained biomass transfers to the second vessel and disperses in the minimal medium.
An aqueous citric acid and sodium citrate buffer replaces the phosphate buffer in the second-stage medium. The buffer is adjusted to pH 6.0 before the recovered biomass is dispersed in it. After the second incubation, a membrane filter separates the biomass from the liquid, and a conductivity measurement guides the sodium chloride addition during formulation.
Four 500 mL vessels each hold a 250 mL first-stage culture. Each harvested biomass portion transfers to a separate vessel containing 100 mL of minimal medium for the second stage. The four second-stage liquids pass through separate clarification filters and collect in a common vessel before saline formulation.
Separate metering pumps feed clarified second-stage supernatant and saline into a static mixer. A downstream sterilizing-grade membrane feeds a closed surge vessel connected to an aseptic unit-dose filling line. The filling line dispenses the blend into individual dropper ampoules and seals them.
The first vessel carries an optical turbidity probe, a pH probe, and a temperature sensor connected to a programmable controller. The controller starts biomass recovery when turbidity reaches a setpoint established from biomass measurements and the culture meets its programmed time, pH, and temperature limits. A load cell measures the recovered biomass, and the controller meters the second-stage medium using a programmed liquid volume per unit mass.
A stirred vessel holds the first culture in a glucose and yeast extract medium at 32 °C for 24 hours. A jacket circulates temperature-controlled water around the vessel.
A centrifuge processes the first culture at 5,000 × g for 10 minutes. The supernatant is decanted, and the cell pellet transfers to the second-stage vessel.
The recovered cells are suspended in water containing 10 mM sodium phosphate buffer at an initial pH of 6.5. The suspension is held at 30 °C for 24 hours.
A centrifuge removes bulk biomass from the second fermentation liquid. The clarified liquid passes through a 0.22 µm membrane that retains residual bacterial cells while dissolved metabolites pass into the filtrate.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A method for obtaining the fermented product according to claim 1, comprising: a) growing an inoculum of Lactobacillus casei or paracasei species, said species comprising in its DNA genome DNA sequences essentially identical to SEQ ID No 1 to 5 in a suitable culture medium, at a temperature ranging from 4 to 40° C., to form a biomass and allowing fermentation of said biomass to proceed for 12 to 36 hours, to form a fermented biomass; b) centrifuging said fermented biomass toA · US 2019/0175670 A1 · claim 9
By way of example only, one or more Lactobacillus species disclosed herein may be inoculated from an agar slant to a suitable nutrient medium and grown to late log phase.B · US 2023/0149481 A1 · ¶ 66
The bacterial cells may be harvested by passing the liquid culture through a filter and the supernatant (“culture filtrate”) may be filter-sterilized, e.g. through 0.2 μm filter, to remove any remaining cells.B · US 2023/0149481 A1 · ¶ 66
c) incubating said pellet fermented biomass into a minimum solution (saline, phosphate buffer, H2O, etc.), preferably comprising a lactate salt, and allowing further fermentation at a temperature ranging from 4 to 40° C., for 12 to 36 hours, preferably for about 24 hours, to get a further fermented biomass;A · US 2019/0175670 A1 · ¶ 31
d) separating said further fermented biomass from a second fermented product by centrifugation.A · US 2019/0175670 A1 · ¶ 32
For example the composition is used for eye drop formulation A, and consists of the second fermented product, diluted to 2-40% vol, preferably 10-25% vol, more preferably 25% vol, in a saline solution or other diluent suitable for the purpose, and properly filtered.A · US 2019/0175670 A1 · ¶ 67
For compositions formulated for topical administration, examples of pharmaceutically acceptable diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphB · US 2023/0149481 A1 · ¶ 92
An empty cell means only that no passage was reproduced there.
The invention relates to the use of the supernatant of Lactobacillus Paracasei in the treatment of conjunctivitis, in particular of Vernal keratoconjunctivitis (VKC).A · US 2019/0175670 A1 · ¶ 2
Therefore, there is a need for new drugs or compounds capable of either preventing or treating conjunctivitis without causing side effects.A · US 2019/0175670 A1 · ¶ 9
There is a continuing need for the development of new and improved therapeutic options for the treatment of inflammatory bowel disease.B · US 2023/0149481 A1 · ¶ 5
Typically, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.B · US 2023/0149481 A1 · ¶ 7
patent.fyi, US 2026/0355264 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355264/, SHA-256 9a086997fbaed2471cab4cae70dec8a30f50f80e1549923a9a000fbd85459ee3